Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in T2DM and CKD: A Secondary Analysis of the SCORED Trial.

Vikas Srinivasan Sridhar Deepak L Bhatt Ayodele Odutayo Michael Szarek Michael J Davies Phillip BanksBertram PittPh Gabriel StegDavid Z I Cherney

Published in: Clinical journal of the American Society of Nephrology : CJASN (2024)

In this exploratory analysis using the complete laboratory dataset, sotagliflozin reduced the risk of kidney and cardiorenal composite endpoints in patients with type 2 diabetes and CKD.

Keyphrases

chronic kidney disease
study protocol
clinical trial
phase iii
randomized controlled trial
glycemic control
skeletal muscle